Sharon Tzelnick1,2, Aviram Mizrachi3,4, Neta Barkan5, Shaked Shivatzki3,4, Eyal Yosefof3,4, Elad Hikri3,4, Joseph Attias5,6, Ohad Hilly3,4. 1. Department of Otorhinolaryngology Head and Neck Surgery, Rabin Medical Center, 39 Jabotinsky St, Petah Tikva, Israel. tzelnicksharon@gmail.com. 2. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. tzelnicksharon@gmail.com. 3. Department of Otorhinolaryngology Head and Neck Surgery, Rabin Medical Center, 39 Jabotinsky St, Petah Tikva, Israel. 4. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 5. Institute of Audiology and Clinical Neurophysiology, Schneider Children's Medical Center of Israel, Petach Tikva, Israel. 6. Department of Communications Sciences and Disorders, Haifa University, Haifa, Israel.
Abstract
PURPOSE: The purpose of this study was to evaluate whether induction of temporary threshold shift (TTS) with aspirin prior to cisplatin exposure can prevent or minimize cisplatin detrimental effects on hearing. METHODS: We randomly divided BALB mice into three groups: (1) cisplatin only, (2) aspirin only, and (3) combined aspirin/cisplatin. Cisplatin was administered as a single intraperitoneal injection of 14 mg/kg. Aspirin was administered for three weeks via intraperitoneal injection of 200 mg/kg sodium salicylate, twice daily. Air conduction thresholds were recorded using Auditory Brainstem Responses (ABR). Cochleae were harvested and cochlear hair cells were counted using a scanning electron microscope (SEM). RESULTS: Aspirin-induced TTS have reached an average of 30.05±16.9 dB after 2 weeks. At 60 days, cisplatin-only treated mice experienced an average threshold shifts of 50.7 dB at 4 kHz, 35.16 dB at 8 kHz, 70 dB at 16 kHz, 53.1 dB at 32 kHz. All threshold shifts were significantly worse than for cisplatin/aspirin treated mice with TTS of 11.85 dB at 4 kHz, 3.58 dB at 8 kHz, 16.58 dB at 16 kHz, 20.41 dB at 32 kHz (p < 0.01). Cochlear cell count with SEM has shown reduction in the number of both inner and outer hair cells in the mid-turn in cisplatin treated mice. CONCLUSION: Aspirin induced TTS can protect from cisplatin-induced ototoxicity. This beneficial effect was demonstrated by auditory thresholds as well as SEM. Larger pre-clinical and clinical studies are still needed to confirm these findings.
PURPOSE: The purpose of this study was to evaluate whether induction of temporary threshold shift (TTS) with aspirin prior to cisplatin exposure can prevent or minimize cisplatin detrimental effects on hearing. METHODS: We randomly divided BALB mice into three groups: (1) cisplatin only, (2) aspirin only, and (3) combined aspirin/cisplatin. Cisplatin was administered as a single intraperitoneal injection of 14 mg/kg. Aspirin was administered for three weeks via intraperitoneal injection of 200 mg/kg sodium salicylate, twice daily. Air conduction thresholds were recorded using Auditory Brainstem Responses (ABR). Cochleae were harvested and cochlear hair cells were counted using a scanning electron microscope (SEM). RESULTS: Aspirin-induced TTS have reached an average of 30.05±16.9 dB after 2 weeks. At 60 days, cisplatin-only treated mice experienced an average threshold shifts of 50.7 dB at 4 kHz, 35.16 dB at 8 kHz, 70 dB at 16 kHz, 53.1 dB at 32 kHz. All threshold shifts were significantly worse than for cisplatin/aspirin treated mice with TTS of 11.85 dB at 4 kHz, 3.58 dB at 8 kHz, 16.58 dB at 16 kHz, 20.41 dB at 32 kHz (p < 0.01). Cochlear cell count with SEM has shown reduction in the number of both inner and outer hair cells in the mid-turn in cisplatin treated mice. CONCLUSION: Aspirin induced TTS can protect from cisplatin-induced ototoxicity. This beneficial effect was demonstrated by auditory thresholds as well as SEM. Larger pre-clinical and clinical studies are still needed to confirm these findings.
Authors: Thomas J Balkany; Adrien A Eshraghi; He Jiao; Marek Polak; Caihong Mou; Dalton W Dietrich; Thomas R Van De Water Journal: Laryngoscope Date: 2005-09 Impact factor: 3.325
Authors: Simon J Crabb; Karen Martin; Julia Abab; Ian Ratcliffe; Roger Thornton; Ben Lineton; Mary Ellis; Ronald Moody; Louise Stanton; Angeliki Galanopoulou; Tom Maishman; Thomas Geldart; Mike Bayne; Joe Davies; Carolynn Lamb; Sanjay Popat; Johnathan K Joffe; Chris Nutting; John Chester; Andrew Hartley; Gareth Thomas; Christian Ottensmeier; Robert Huddart; Emma King Journal: Eur J Cancer Date: 2017-11-10 Impact factor: 9.162
Authors: Werner Bader; Timo Gottfried; Gerald Degenhart; Lejo Johnson Chacko; Daniel Sieber; Herbert Riechelmann; Natalie Fischer; Romed Hoermann; Rudolf Glueckert; Anneliese Schrott-Fischer; Joachim Schmutzhard Journal: Front Neurol Date: 2021-01-11 Impact factor: 4.003
Authors: Richard Engelman; Robert A Baker; Donald S Likosky; Alina Grigore; Timothy A Dickinson; Linda Shore-Lesserson; John W Hammon Journal: J Extra Corpor Technol Date: 2015-09